ArticleCirculation reports2026
Clinical Impact of Hospital-Associated Disability in Patients With Acute Decompensated Heart Failure.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hospital-associated disability (HAD) may affect long-term outcomes in heart failure (HF), but evidence remains limited, so in this study we aimed to evaluate the impact of HAD on long-term outcomes in acute decompensated HF (ADHF). Methods and Results: We analyzed data from the Japanese Registry of Acute Decompensated Heart Failure (JROADHF), including patients enrolled from January 2013 to December 2017. HAD was defined as a decline of ≥5 points in the Barthel Index from admission to discharge. The primary outcome was all-cause death, and the secondary outcomes were cardiovascular (CV) death, non-CV death, and HF readmission. Of the 8,965 patients enrolled (mean age 76.9±12.7 years; 54.8% male), 537 (6.0%) had HAD. In the multivariate analysis, HAD was independently associated with all-cause death (hazard ratio [HR]: 1.58; 95% confidence interval [CI]: 1.31-1.91; P<0.001) and non-CV death (HR: 1.44; 95% CI: 1.08-1.92; P=0.013), but not with CV death or HF readmission. Subgroup analyses revealed a stronger association between HAD and all-cause death in patients under 80 years (<80 years: HR: 2.48; 95% CI: 1.80-3.41; ≥80 years: HR: 1.36; 95% CI: 1.09-1.71; P for interaction <0.001). Conclusions: HAD significantly affects the long-term mortality rate in ADHF patients, particularly in those under 80 years of age. These findings highlight the importance of considering age-specific management approaches in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.